Expression of the five different somatostatin receptor subtypes in endocrine cells of the pancreas

Applied Immunohistochemistry and Molecular Morphology

Volumn 8, Issue 2, 2000, Pages 126-132

  Portela Gomes, Guida M ^a   Stridsberg, Mats ^a   Grimelius, Lars ^a   Öberg, Kjell ^a   Janson, Eva T ^a  

^a UPPSALA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Antibodies; Diabetes mellitus; Endocrine cells; Immunocytochemistry; Islet; Pancreas; Somatostatin; Somatostatin receptor

Indexed keywords

ANTIBODY; GLUCAGON; INSULIN; PANCREAS POLYPEPTIDE; RECEPTOR SUBTYPE; SOMATOSTATIN; SOMATOSTATIN RECEPTOR;

ARTICLE; DIABETES MELLITUS; ENDOCRINE CELL; ENDOCRINE DISEASE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOCYTOCHEMISTRY; IMMUNOFLUORESCENCE; PANCREAS CELL; PANCREAS ISLET ALPHA CELL; PANCREAS ISLET BETA CELL; PANCREAS ISLET DELTA CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; RABBIT;

ANIMALS; ANTIBODY SPECIFICITY; GLUCAGON; HUMANS; IMMUNOHISTOCHEMISTRY; INSULIN; ISLETS OF LANGERHANS; PANCREATIC POLYPEPTIDE; RABBITS; RECEPTORS, SOMATOSTATIN; SOMATOSTATIN; SOMATOSTATIN-SECRETING CELLS;

EID: 0033862095     PISSN: 10623345     EISSN: None     Source Type: Journal    
DOI: 10.1097/00022744-200006000-00007     Document Type: Article

References (28)

1. Brazeau P, Vale W, Burgus R, et al. Hypothalamic polypeptide that inhibits the secretion of immunoreactive pituitary growth hormone. Science 1973;179:77-9.
2. Boden G, Sivitz MC, Owen OE, Essa-Koumar N, Landor JH. Somatostatin suppresses secretin and pancreatic exocrine secretion. Science 1975;190:163-5.
3. Polak JM, Pearse AGE, Grimelius L, Bloom SR, Arimura A. Growth-hormone release-inhibiting hormone in gastrointestinal and pancreatic D cells. Lancet 1975;1:1220-2.
4. Yamada Y, Post SR, Wang K, Tager HS, Bell GI, Seino S. Cloning and functional characterization of a family of human and mouse somatostatin receptors expressed in brain, gastrointestinal tract, and kidney. Proc Natl Acad Sci U S A 1992;89:251-5.
5. Yamada Y, Reisine T, Law SF, et al. Somatostatin receptors, an expanding gene family: cloning and functional characterization of human sstR3, a protein coupled to adenylyl cyclase. Mol Endocrinol 1992;6:2136-42.
6. Yamada Y, Kagimoto S, Kubota A, et al. Cloning, functional expression and pharmacological characterization of a fourth (hsstR4) and a fifth (hsstR5) human somatostatin receptor subtype. Biochem Biophys Res Commun 1993;95:844-52.
7. Lamberts SWJ, van der Lely AJ, de Herder WW, Hofland LJ, Octreotide. N Engl J Med 1996;334:246-54.
8. Chen C, Vincent JD, Clarke IJ. Ion channels and the signal transduction pathways in the regulation of growth hormone secretion. Trends Endocrinol Metab 1994;5:227-33.
9. Buscail L, Delesque N, Estève JP, et al. Stimulation of tyrosine phosphatase and inhibition of cell proliferation by somatostatin analogues: mediation by human somatostatin receptor subtypes sstR1 and sstR2. Proc Natl Acad Sci U S A 1994;91:2315-9.
10. Buscail L, Estève JP, Saint-Laurent N, et al. Inhibition of cell proliferation by the somatostatin analogue RC-160 is mediated by somatostatin receptor subtypes SSRT2 and sstR5 through different mechanisms. Proc Natl Acad Sci U S A 1995;92:1580-4.
11. Sharma K, Patel YC, Srikant CB. Subtype-elective induction of wild-type p53 and apoptosis, but not cell cycle arrest, by human somatostatin receptor 3. Mol Endocrinol 1996;10:1688-96.
12. Sharma K, Srikant CB. Induction of wild-type p53, Bax and acidic endonuclease during somatostatin-signaled apoptosis in MCF-7 human breast cancer cells. Int J Cancer 1998;76:259-66.
13. Patel YC. Molecular pharmacology of somatostatin receptor subtypes. J Endocrinol Invest 1997;20:348-67.
14. Janson ET, Stridsberg M, Gobi A, Westlin JE, Öberg K. Determination of somatostatin receptor subtype 2 in carcinoid tumors by immunohistochemical investigation with somatostatin receptor subtype 2 antibodies. Cancer Res 1998;58:2375-8.
15. Hofland LJ, Liu Q, van Koetsveld PM, et al. Immunohistochemical detection of somatostatin receptor subtypes sst1 and sst2A in human somatostatin receptor positive tumors. J Clin Endocrinol Metab 1999;84:775-80.
16. 3 in paraffin-embedded breast cancer tissue using subtype-specific antibodies. Clin Cancer Res 1998;4:2047-52.
17. Reubi JC, Kappeler A, Waser B, Schonbrunn A, Laissue J. Immunohistochemical localization of somatostatin receptor sst2A in human pancreatic islets. J Clin Endocrinol Metab 1998;83:3746-9.
18. Kumar U, Sasi R, Suresh S, et al. Subtype-selective expression of the five somatostatin receptors (hsstR1-5) in human pancreatic islet cells. A quantitative double-label immunohistochemical analysis. Diabetes 1999;48:77-85.
19. O'Shaughnessy DJ. Radioimmunoassay of gut regulatory peptides. In: Bloom SR, Long RG, eds. Antibodies. London: W.B. Saunders, 1982:11-20.
20. Vaitukaitis J, Robbins JB, Nieschlag E, Ross GT. A method for producing specific antisera with small doses of immunogen. J Clin Endocrinol 1971;33:988-91.
21. Adams JC. Biotin amplification of biotin and horseradish peroxidase signals in histochemical stains. J Histochem Cytochem 1992; 40:1457-63.
22. Bobrow MN, Harris TD, Shaughnessy KJ, Litt GJ. Catalyzed reporter deposition, a novel method of signal amplification. Application to inununoassays. J Immunol Methods 1989;125:279-85.
23. Hsu SM, Raine T, Fanger H. Use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase techniques: a comparison between ABC and unlabeled (PAP) procedures. J Histochem Cytochem 1981;29:577-80.
24. Bell GI, Yasuda K, Kong H, Law SF, Raynor K, Reisine T. Molecular biology of somatostatin receptors. Ciba Found Symp 1995; 190:65-79.
25. Atiya AW, Moldovan S, Adrian TE, Coy D, Walsh J, Brunicardi FC. Intraislet somatostatin inhibits insulin (via a subtype-2 somatostatin receptor) but not islet amyloid polypeptide secretion in the isolated perfused human pancreas. J Gastrointest Surg 1997;3: 251-6.
26. Lunetta M, Di Mauro M, Le Moli R. Different effect of octreotide by continuous night infusion at increasing rate or by evening injections at different times on morning hyperglycemia and growth hormone levels in insulin-dependent diabetic patients. J Endocrinol Invest 1998;21:454-8.
27. Candrina R, Giustina G. Effects of a long-acting somatostatin analogue (SMS 201-995) on glycemic and hormonal profiles in insulin-treated type II diabetic patients. J Endocrinol Invest 1988;11: 501-7.
28. Kirkegaard C, Nörgaard K, Snorgaard O, Bek T, Larsen M, Lund Andersen H. Effect of one year continuous subcutaneous infusion of a somatostatin analogue, octreotide, on early retinopathy, metabolic control, and thyroid function in type 1 (insulin-dependent) diabetes mellitus. Acta Endocrinol 1990;122:766-72.